Align Technology (ALGN)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$164.90+8.79%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
Research Workspace
Put ALGN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Supplies is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 4% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 16%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskHealthy across the board
Align Technology's profitable revenue growth has to keep compounding to justify the price. Revenue growth is slowing, falling from 6.2% to 1.9% year over year. The company still beat its Q3 earnings estimate by 20.7%. It trades at 15 times earnings versus a 22 times peer median. The price reflects less growth than our forecast suggests. Weak demand threatens the 3% to 4% revenue growth target. Peer multiples imply a price about 12% above where it trades. Our read remains intact.
Trailing returns as of 2026-11-04. ALGN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 16 analysts currently covering ALGN (as of Nov 2026).
Based on 7 Wall Street analysts offering 12-month price targets for ALGN in the last 4 months.
Continue this research
Compare ALGN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ALGN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Supplies — fair value, gap to price, and forward P/E.
Compare the value case
Put ALGN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive profitable revenue growth
2026 revenue outlook supports profitable growth; CEO transition and mouthguard pilot are secondary developments.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $164.90
The last 12 months of price, then the range of analyst 12-month targets from today’s $164.90.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Achieve 3% to 4% revenue growth in 2026
Revenue beat modestly supports growth, though one quarter does not establish 2026 delivery.
Patent win supports protection of Align’s intellectual property and competitive position, but financial impact is uncertain.
Threatens: Achieve 3% to 4% revenue growth in 2026
Weak demand impacts revenue growth objective.
Threatens: Achieve 3% to 4% revenue growth in 2026
Weak demand impacts revenue growth objective.
Threatens: Achieve 3% to 4% revenue growth in 2026
Stock slide indicates potential revenue concerns.
Advances: Achieve 3% to 4% revenue growth in 2026
Invisalign growth supports revenue growth objective.
Strengthens market position and protects revenue growth potential.
